Natco Pharma Limited Approved  The Generic Version Of Vidaza

Express News Global

updated:27,2017 15:45 IST


Hyderabad: Natco Pharma Limited on Tuesday said it got the last endorsement of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (FDA) for the non specific form of Vidaza (Azacitidine for Injection, 100mg for every Vial), single-Dose Vial.

As indicated by an announcement issued by the medication producer, Natco and its promoting accomplice Breckenridge Pharmaceutical, Inc. (BPI) plan to dispatch this item in the USA advertise soon.

Vidaza by Celgene Corporation is a remedy hostile to growth chemotherapy medicate that is shown to treat, myelodysplastic disorder (MDS).

Vidaza created add up to joined offers of $188 million for the twelve-month time frame finishing April 2017, in view of industry deals information.

Natco shares are exchanging at Rs. 969.25 each on BSE at 14.30 hrs down 0.33 for every penny over past close.